Literature DB >> 33773806

Small Molecule Drug Discovery for Neglected Tropical Snakebite.

Rachel H Clare1, Steven R Hall1, Rohit N Patel1, Nicholas R Casewell2.   

Abstract

Snakebite envenoming is responsible for as many as 138 000 deaths annually, making it the world's most lethal neglected tropical disease (NTD). There is an urgent need to improve snakebite treatment, which currently relies on outdated and poorly tolerated biologic antivenoms that are often weakly efficacious, must be given intravenously in a healthcare setting, and are expensive to those who need them the most. Herein we describe the challenges associated with the discovery and development of new snakebite treatments and detail the great potential of venom toxin-inhibiting small molecule drugs. We finish by highlighting successful enabling strategies applied to other NTDs that could be exploited to facilitate the development of next-generation small molecule-based snakebite treatments.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  biological toxins; drug development; enabling strategies; neglected topical diseases; snake venom; therapeutic discovery

Mesh:

Substances:

Year:  2021        PMID: 33773806     DOI: 10.1016/j.tips.2021.02.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  3 in total

1.  Exploring the Utility of ssDNA Aptamers Directed against Snake Venom Toxins as New Therapeutics for Snakebite Envenoming.

Authors:  Nessrin Alomran; Raja Chinnappan; Jaffer Alsolaiss; Nicholas R Casewell; Mohammed Zourob
Journal:  Toxins (Basel)       Date:  2022-07-08       Impact factor: 5.075

Review 2.  The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming.

Authors:  José María Gutiérrez; Laura-Oana Albulescu; Rachel H Clare; Nicholas R Casewell; Tarek Mohamed Abd El-Aziz; Teresa Escalante; Alexandra Rucavado
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

3.  In vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus.

Authors:  Stefanie K Menzies; Rachel H Clare; Chunfang Xie; Adam Westhorpe; Steven R Hall; Rebecca J Edge; Jaffer Alsolaiss; Edouard Crittenden; Amy E Marriott; Robert A Harrison; Jeroen Kool; Nicholas R Casewell
Journal:  Toxicon X       Date:  2022-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.